Abstract Library

#4506 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. streptozocin-based chemotherapies (STZ-BC) as first-line (1L) treatment for advanced grade 2/3 (G2/G3) pancreatic NETs (pNETs)

Introduction: The NETTER-2 trial showed improved progression-free survival (PFS) with 1L 177Lu-DOTATATE vs. high dose octreotide in advanced G2/G3 pNETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments, such as STZ-BC, hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Navalkissoor S

Authors: Navalkissoor S, Capdevila J, Deshayes E, Gerard L, Srirajaskanthan R,

Keywords: pancreatic neuroendocrine tumour, [177lu]lu-dotatate, streptozocin, 5-fluorouracil, matching adjusted indirect comparison,

#4504 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. CAPTEM as first-line (1L) treatment for advanced grade 3 (G3) gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Introduction: The NETTER-2 trial showed a significant progression-free survival (PFS) benefit with 1L 177Lu-DOTATATE vs. high dose octreotide for patients with advanced G2/G3 GEP-NETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments for patients with G3 GEP-NETs, such as capecitabine + temozolomide (CAPTEM), hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Deshayes E

Authors: Deshayes E, Capdevila J, Gerard L, Navalkissoor S, Srirajaskanthan R,

Keywords: gastroenteropancreatic neuroendocrine tumour, [177lu]lu-dotatate, capecitabine, temozolomide, matching adjusted indirect comparison,

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,

#4449 Treatment of MiNEN with peptide receptor radionuclide therapy

Introduction: Mixed non-neuroendocrine and neuroendocrine neoplasms (MiNENs) of gastrointestinal tract are rare tumours with characteristic histological features include at least 30% of both neuroendocrine and non-neuroendocrine components of the whole neoplasm. They are usually treated with surgical resection and chemotherapy in advanced disease. However, there is scarcity of data for the use of peptide receptor radionuclide therapy (PRRT) in these tumours.

Conference:

Presenting Author: Shekhda K

Authors: Shekhda K, Luong T, Paterson A, Navalkissoor S, Krell D,

Keywords: MiNEN, PRRT, DOTATATE,

#4343 Ga68-DOTATATE imaging on a state-of-the-art total-body PET/CT scanner with reducing administered activity

Introduction: Long-field of view PET/CT scanners allows total body scanning resulting higher sensitivity than traditional PET/CT scanners offering possible lower dose and faster scans.

Conference:

Presenting Author: Santillan N

Authors: Navalkissoor S, Santillan N, Chowdhury A, Ferreira B, Toumpanakis C,

Keywords: SSR, Ga68 DOTATATE, Neuroendocrine tumour, Quadra,